Diabetes Medicine Update
Jardiance and Jardiamet medicines now funded for high risk type 2 diabetes patients As of 1st February this year, empagliflozin – a medicine used to treat type 2 diabetes – is fully funded for people who meet the funding criteria. This makes a potentially life-saving medicine accessible to more New Zealanders. Eligible patients will only […]